Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Nanopore Technologies Raises £84.4M in Private Financing

NEW YORK – Oxford Nanopore Technologies said on Tuesday that it has raised £84.4 million ($109.5 million) in a private financing from existing and new investors.

Investors in the round included International Holdings Company (IHC), based in Abu Dhabi, United Arab Emirates, and RPMI Railpen, a UK pension fund.

The company will use the new funds to support the ramp of commercial and manufacturing operations and to further develop its nanopore technology. It is currently scaling up its LamPore COVID-19 diagnostic test for the detection of SARS-CoV-2, which obtained the CE mark last week.

The latest financing comes after the company raised £48.4 million ($62.8 million) from new and existing investors in May and brings Oxford Nanopore's total funding raised to date to approximately £614 million.

"Our international investor base reflects the international ambitions of Oxford Nanopore, as our technology is now used to answer important biological questions in more than 100 countries," said Oxford Nanopore CEO Gordon Sanghera in a statement.

"Oxford Nanopore has developed distinctive and proven technology and has been highly effective in taking products from innovation to market within tight timeframes," commented IHC Managing Director and CEO Syed Basar Shueb.

Oxford Nanopore said it will provide updates on its technology later this month at the American Society of Human Genetics virtual annual meeting.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.